Stocklytics Platform
Asset logo for symbol VYGR
Voyager Therapeutics
VYGR82
$5.75arrow_drop_up1.23%$0.06
High Value
Asset logo for symbol VYGR
VYGR82

$5.75

arrow_drop_up1.23%

Performance History

Chart placeholder
Key Stats
Open$5.69
Prev. Close$5.69
EPS0.66
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range5.52
5.86
52 Week Range5.19
11.72
Ratios
EPS0.66

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Voyager Therapeutics (VYGR)

Voyager Therapeutics Inc (VYGR) is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. With a deep understanding of the biology of the central nervous system, Voyager is pioneering a new approach to treating these devastating conditions. The company's innovative gene therapy platform enables the delivery of therapeutic genes directly to the brain, potentially offering a one-time treatment solution. Through strategic partnerships and a robust pipeline of product candidates, Voyager is at the forefront of the gene therapy revolution.
Founded in 2014, Voyager has quickly established itself as a leader in the field. The company's stock price history reflects its steady growth and investor confidence in its groundbreaking therapies. Voyager's commitment to rigorous scientific analysis is evident in its extensive stock analysis, which provides detailed insights into the company's financial performance and future prospects. With a market cap of XX billion, Voyager is well positioned to capitalize on the growing demand for innovative neurological treatments.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Headquarters
Cambridge
Employees
125
Exchange
NASDAQ
add Voyager Therapeutics  to watchlist

Keep an eye on Voyager Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Voyager Therapeutics 's (VYGR) price per share?

The current price per share for Voyager Therapeutics (VYGR) is $5.75. The stock has seen a price change of $0.07 recently, indicating a 1.23% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Voyager Therapeutics (VYGR)?

For Voyager Therapeutics (VYGR), the 52-week high is $11.72, which is 103.83% from the current price. The 52-week low is $5.19, the current price is 10.79% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Voyager Therapeutics (VYGR) a growth stock?

Voyager Therapeutics (VYGR) has shown an average price growth of -4.38% over the past three years. It has received a score of 83 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Voyager Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Voyager Therapeutics (VYGR) stock price performance year to date (YTD)?

As of the latest data, Voyager Therapeutics (VYGR) has a year-to-date price change of -36.11%. Over the past month, the stock has experienced a price change of 7.28%. Over the last three months, the change has been -8%. Over the past six months, the figure is -26.19%. Looking at a longer horizon, the five-year price change stands at -58.99%.
help

Is Voyager Therapeutics (VYGR) a profitable company?

Voyager Therapeutics (VYGR) has a net income of $132.33M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -55.95% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $250.01M, although specific revenue growth data is currently not available. The gross profit is $245.57M. Operating income is noted at $122.01M. Furthermore, the EBITDA is $126.46M.
help

What is the market capitalization of Voyager Therapeutics (VYGR)?

Voyager Therapeutics (VYGR) has a market capitalization of $314.1M. The average daily trading volume is 5.74, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level